Immunoact

Immunoact Pioneers of India's First CAR-T Cell Therapy

27/03/2026

Redefining how patients access life-saving innovation.
For the first time in India, ImmunoACT in partnership with Sciences introduce a Value-Based Care Program for NexCAR19—designed to align treatment with outcomes.

This means assured rebate in event of death or disease progression

This isn’t about doubt. It’s about confidence in the science and a commitment to accountability in care.

With comparable efficacy and a favourable safety profile, NexCAR19 is backed by strong real-world evidence from treating over 600 patients—and now, a model that ensures patients pay for results, not risk.

Because access to advanced therapies should be fair, transparent, and patient-first.

Swipe to debunk the myths about CAR-T cell therapy! ➡️There is a lot of information out there about how this treatment w...
26/03/2026

Swipe to debunk the myths about CAR-T cell therapy! ➡️

There is a lot of information out there about how this treatment works. We’re clearing up the most common misconceptions to help you understand the facts.

Knowledge is the first step toward better care. 🩺

Save this post for later and share it with someone who wants to learn more! 💡

12/03/2026

Celebrating Access: Two New Patients onboarded through the “The Hope Initiative”
We are pleased to announce the enrolment of two new patients under The Hope Initiative—a strategic collaboration between ImmunoACT and Mango Sciences to expand access to , the world’s first humanized CAR-T cell therapy.
These milestones reflect our commitment to making advanced, life-saving therapies not only scientifically possible but also financially accessible.
Recent patient enrolments across Delhi NCR and Mumbai highlight the program’s impact:
• Rapid Financing: A 0% interest loan of ₹10 Lakhs sanctioned within a day of document submission.
• Clinical Progress: Both patients have successfully completed the apheresis stage.
• Seamless Support: Financial assistance is finalized before infusion, ensuring an uninterrupted treatment journey.

At ImmunoACT, we believe innovation matters most when every eligible patient has a pathway to access it.

𝗛𝗼𝗽𝗲. 𝗣𝗲𝗿𝘀𝗲𝘃𝗲𝗿𝗮𝗻𝗰𝗲. 𝗔𝗻𝗱 𝘁𝗵𝗲 𝗰𝗼𝘂𝗿𝗮𝗴𝗲 𝘁𝗼 𝗯𝗲𝗴𝗶𝗻 𝗮𝗴𝗮𝗶𝗻. For Vishal, an MPPSC aspirant from Indore, life once revolved around...
11/03/2026

𝗛𝗼𝗽𝗲. 𝗣𝗲𝗿𝘀𝗲𝘃𝗲𝗿𝗮𝗻𝗰𝗲. 𝗔𝗻𝗱 𝘁𝗵𝗲 𝗰𝗼𝘂𝗿𝗮𝗴𝗲 𝘁𝗼 𝗯𝗲𝗴𝗶𝗻 𝗮𝗴𝗮𝗶𝗻.

For Vishal, an MPPSC aspirant from Indore, life once revolved around books, preparation, and the dream of serving through civil service.

In 2020, that journey was interrupted when he was diagnosed with B-cell Acute Lymphoblastic Leukemia (B-ALL). Chemotherapy brought temporary relief, but the disease relapsed. Even after a bone marrow transplant in 2024, the leukemia returned - leaving limited treatment options.

At MGM Medical College, Indore, his doctors explored CAR-T cell therapy. Vishal went on to receive NexCAR19, ImmunoACT’s indigenous CAR-T therapy developed through collaboration between IIT Bombay and Tata Memorial Hospital.
Nearly a year after the infusion, Vishal remains in complete remission.

Today, he has returned to his books, once again preparing for the MPPSC exams - rebuilding the future that illness had once paused. His journey reflects the power of resilience, scientific innovation, and the hope that advanced therapies can bring to patients.

At ImmunoACT, stories like Vishal’s remind us why innovation matters.
Innovation with purpose.
Hope for All.

𝗥𝗲𝗮𝗱 𝗩𝗶𝘀𝗵𝗮𝗹’𝘀 𝗳𝘂𝗹𝗹 𝘀𝘁𝗼𝗿𝘆 𝗵𝗲𝗿𝗲: https://www.ians.in/vmpl/renewed-hope-an-indore-mppsc-aspirants-recovery-after-relapsed-leukemia

Our Founder, Dr. Rahul Purwar, will be speaking at the 𝟴𝘁𝗵 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗼𝗻 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 (𝗜𝗦𝗖𝗦𝗚𝗖𝗢𝗡 𝟮𝟬𝟮𝟲), contr...
10/03/2026

Our Founder, Dr. Rahul Purwar, will be speaking at the 𝟴𝘁𝗵 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗼𝗻 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 (𝗜𝗦𝗖𝗦𝗚𝗖𝗢𝗡 𝟮𝟬𝟮𝟲), contributing to global scientific discussions on the translational impact of next-generation cell and gene therapies.

📅 14–15 March 2026
📍 Taj Deccan, Hyderabad

At this session, Dr. Purwar will deliver a talk titled “CAR-T Cell Therapy – First Indigenous Gene Therapy: Discovery, Translation and Impact on Society.”

He will share insights from ImmunoACT’s journey in developing homegrown CAR‑T cell therapy, highlighting how indigenous innovation, deep translational science, and mission-driven ex*****on can build affordable, world-class cancer treatment rooted in India and relevant worldwide.

This conference will bring together leading scientists, clinicians, and researchers to discuss cutting-edge advances in stem cell science and regenerative medicine. We look forward to meaningful scientific exchange and collaborations that will help shape the future of scalable, science-led healthcare innovation.

10/03/2026

Dr. Akshay Lahoti, thank you for sharing this powerful milestone — your patient completing one full year of remission after battling relapsed Acute Lymphoblastic Leukemia (ALL).

One year of remission is:
* A family sleeping peacefully again.
* A patient planning a future again.
* Science doing what it was meant to do - restoring hope.

At , when we speak about , we talk about innovation, access, and real-world evidence. But moments like this remind us why that work truly matters.

In India, access to advanced therapies like CAR-T has historically been limited by cost, infrastructure readiness, manufacturing timelines, and the need to travel to a handful of major metro centers. The real question has always been - can we bring breakthrough science closer to home?

What happened in Indore one year ago is that answer. Bringing CAR-T to Madhya Pradesh means patients no longer need to travel thousands of kilometres in search of advanced care, families do not have to uproot their lives during an already fragile time, and world-class hematology treatment becomes available locally - closer to patients’ support systems.

Dr. Lahoti, MGM Medical College and every stakeholder who made this possible - thank you for your conviction. And to the brave patient who placed trust in science at the most difficult moment - you are the true hero of this story.

At ImmunoACT, we believe deeply in: Innovation with purpose and Hope for All.

Today, that hope stands one year strong at MGM Medical College.

𝗥𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝗰𝗲. 𝗦𝗲𝗰𝗼𝗻𝗱 𝗖𝗵𝗮𝗻𝗰𝗲𝘀. 𝗔𝗻𝗱 𝘁𝗵𝗲 𝗿𝗼𝗮𝗱 𝗯𝗮𝗰𝗸 𝘁𝗼 𝗹𝗶𝗳𝗲.For Pradeep Singh, a national-level cyclist, life once revolved ar...
10/03/2026

𝗥𝗲𝘀𝗶𝗹𝗶𝗲𝗻𝗰𝗲. 𝗦𝗲𝗰𝗼𝗻𝗱 𝗖𝗵𝗮𝗻𝗰𝗲𝘀. 𝗔𝗻𝗱 𝘁𝗵𝗲 𝗿𝗼𝗮𝗱 𝗯𝗮𝗰𝗸 𝘁𝗼 𝗹𝗶𝗳𝗲.

For Pradeep Singh, a national-level cyclist, life once revolved around endurance, discipline, and the thrill of the road.

But in 2021, everything changed when he was diagnosed with Acute Lymphoblastic Leukemia (ALL).

After months of treatment, the disease initially went into remission. Yet two years later, it returned - bringing uncertainty and difficult choices once again.

At Tata Memorial Hospital, Mumbai, Pradeep was evaluated for , the world’s first humanized CAR-T cell therapy developed and manufactured in India.

Within weeks of receiving the therapy, his recovery began. Today, more than a year later, Pradeep remains in remission and has returned to something he once feared he might lose forever - cycling. His journey reflects more than personal determination. It represents what becomes possible when scientific innovation, clinical expertise, and patient courage come together.

As India’s biomedical ecosystem grows, indigenous innovations like CAR-T therapy are helping bring advanced cancer treatments closer to patients - expanding access while building global-class science within the country.

At , stories like Pradeep’s remind us why innovation matters.
Innovation with purpose.
Hope for all.

𝗥𝗲𝗮𝗱 𝗣𝗿𝗮𝗱𝗲𝗲𝗽 𝗦𝗶𝗻𝗴𝗵’𝘀 𝗳𝘂𝗹𝗹 𝘀𝘁𝗼𝗿𝘆 𝗵𝗲𝗿𝗲: https://newsindianlink.co.in/back-on-the-road-how-an-indian-made-cancer-therapy-helped-a-young-cyclist-restart-his-life/

𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵. 𝗖𝗼𝘂𝗿𝗮𝗴𝗲. 𝗔𝗻𝗱 𝘁𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝗸𝗲𝗲𝗽 𝗴𝗼𝗶𝗻𝗴 This 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗗𝗮𝘆, we celebrate a woman who refused to give ...
06/03/2026

𝗦𝘁𝗿𝗲𝗻𝗴𝘁𝗵. 𝗖𝗼𝘂𝗿𝗮𝗴𝗲. 𝗔𝗻𝗱 𝘁𝗵𝗲 𝗽𝗼𝘄𝗲𝗿 𝘁𝗼 𝗸𝗲𝗲𝗽 𝗴𝗼𝗶𝗻𝗴

This 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗪𝗼𝗺𝗲𝗻’𝘀 𝗗𝗮𝘆, we celebrate a woman who refused to give up - even when cancer returned.

When Dr. Arora’s Non-Hodgkin’s Lymphoma returned after multiple lines of treatment, the road ahead was uncertain. Yet she chose to keep fighting - placing her trust in science and in a new possibility: , a humanized CAR-T cell therapy developed and manufactured in India.

Today, she has been in remission for more than two and a half years.

Her story is a reminder that behind every scientific breakthrough is something deeply human - hope, courage, and the determination to move forward.

Stories like these are also made possible by the many women working tirelessly across science, clinical care, operations, and patient support - researchers in the lab, physicians at treatment centers, nurses at the bedside, coordinators guiding families through complex treatment journeys, and teams working every day to make advanced therapies more accessible.

At , we are proud to work alongside remarkable women who are helping bring cell and gene therapies closer to patients across India.

This Women’s Day, we celebrate:
• Women who fight cancer with courage
• Women who care for patients with compassion
• Women who push the boundaries of science

Together, they remind us why innovation matters.
Innovation with purpose. Hope for all.

Read the full story here: https://manufacturing.economictimes.indiatimes.com/amp/news/life-sciences/indigenous-car-t-therapy-signals-new-phase-for-indias-cancer-care-and-biotech-manufacturing/128606914

05/03/2026

𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝗶𝘁 𝘁𝗮𝗸𝗲 𝘁𝗼 𝗯𝗿𝗶𝗻𝗴 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗼𝗿𝗹𝗱’𝘀 𝗺𝗼𝘀𝘁 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗰𝗹𝗼𝘀𝗲𝗿 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀’ 𝗵𝗼𝗺𝗲𝘀 𝗶𝗻 𝗜𝗻𝗱𝗶𝗮?

Science.
Collaboration.
And patients like Vishal, whose courage and faith in science make progress possible.

Vishal’s journey reflects the strength of patients facing difficult diagnoses - and the commitment of clinicians, scientists, and innovators working to expand treatment possibilities. His experience with - the world’s first humanized CAR-T cell therapy - demonstrates what becomes possible when cutting-edge science and clinical collaboration come together.

At ImmunoACT, our mission has been clear from the start: build globally competitive therapies in India, for the world. Through indigenous innovation, robust manufacturing, and an integrated vein-to-vein model, we are working to make advanced CAR-T therapy more accessible and scalable.

Today, We have treated over 600 patients, and an extensive network of 90+ onboarded institutions across the country is helping bring this breakthrough therapy closer to patients’ homes. Expanding access across India’s vast geography remains central to our vision. What was once considered one of the most complex and inaccessible frontiers in medicine is now steadily becoming a reality in India.

Stories like Vishal’s remind us why this work matters - ensuring that world-class innovation can reach every patient who needs it.

04/03/2026

Dr. Akshay Lahoti, thank you for sharing this powerful milestone — your patient completing one full year of remission after battling relapsed Acute Lymphoblastic Leukemia (ALL).

One year of remission is:
* A family sleeping peacefully again.
* A patient planning a future again.
* Science doing what it was meant to do - restoring hope.

At , when we speak about , we talk about innovation, access, and real-world evidence. But moments like this remind us why that work truly matters.

In India, access to advanced therapies like CAR-T has historically been limited by cost, infrastructure readiness, manufacturing timelines, and the need to travel to a handful of major metro centers. The real question has always been - can we bring breakthrough science closer to home?

What happened in Indore one year ago is that answer. Bringing CAR-T to Madhya Pradesh means patients no longer need to travel thousands of kilometres in search of advanced care, families do not have to uproot their lives during an already fragile time, and world-class hematology treatment becomes available locally - closer to patients’ support systems.

Dr. Lahoti, MGM Medical College and every stakeholder who made this possible - thank you for your conviction. And to the brave patient who placed trust in science at the most difficult moment - you are the true hero of this story.

At ImmunoACT, we believe deeply in: Innovation with purpose and Hope for All.

Today, that hope stands one year strong at MGM Medical College.

We are pleased to share coverage from The Hindu highlighting key discussions at BioAsia 2026, where our President, V. Si...
26/02/2026

We are pleased to share coverage from The Hindu highlighting key discussions at BioAsia 2026, where our President, V. Simpson E., spoke about India’s growing capability to manufacture advanced therapies such as CAR-T at scale.

In a panel examining the future of next-generation therapies, Simpson emphasized that CAR-T represents a radical departure from conventional pharmaceutical manufacturing. Unlike traditional biologics, cell and gene therapies demand entirely new production models, integrated ecosystems, and precision-led ex*****on.

At , this shift is already in motion. has now treated over 600 patients, supported by one of the world’s fastest vein-to-vein timelines and manufacturing efficiency that surpasses global benchmarks.
These milestones signal that India is evolving from being a manufacturing backbone to becoming a builder of complex, scalable innovation.

At ImmunoACT, we are scaling responsibly - transforming a Made-in-India breakthrough into a globally relevant therapy while keeping access, quality, and scientific rigor at the core.
Innovation with purpose.
Hope for all.

Image Source: The Hindu | Hyderabad Edition | February 17, 2026.

Proud to witness the ripple effects of Indian innovation reaching new frontiers. Cipla South Africa's successful academi...
26/02/2026

Proud to witness the ripple effects of Indian innovation reaching new frontiers.

Cipla South Africa's successful academic CAR-T event marks a crucial milestone in our shared mission: bringing Made-in-India, world-class cell and gene therapy to patients across the world.

NexCAR19 - the world’s first humanized CAR-T therapy - stands as a testament to what indigenous innovation can achieve when anchored in purpose. Together, ImmunoACT and Cipla are not just introducing a therapy; we are helping build the scientific and clinical ecosystems required for lasting impact.

Our sincere thanks to the entire Cipla team for leading this important initiative with vision and responsibility.
As India steps forward in global biotech leadership, we remain guided by one belief:
Innovation with purpose. Hope for all.

-T

Image Source: https://www.linkedin.com/posts/cipla-africa_cipla-recently-hosted-an-academic-summit-activity-7431579938475884544-O951?utm_source=share&utm_medium=member_desktop&rcm=ACoAADn_F4cBCksWSTcdG1GKnIYWpt4I_gYWXL4

Address


410206

Website

Alerts

Be the first to know and let us send you an email when Immunoact posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Want your business to be the top-listed Engineering Company?

Share